Ribomic Profit Margin

The latest profit margin for 4591.T is -15852.13% as of June 2026. That compares with -163513.51% in the prior-year period — up 90.3% year over year. That is below the Healthcare sector average of 9.71%. Investors often review this figure alongside Ribomic's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4591.T's profit margin moved from -163513.51% to -15852.13% — a 90.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ribomic's valuation or profitability profile.

Against Healthcare companies, 4591.T currently prints -15852.13% for profit margin, while the sector average sits near 9.71%. That is roughly 163423.1% below the sector mean. Large gaps often invite a closer look at Ribomic's growth, margins, and balance sheet.

Profit Margin shows how effectively Ribomic converts resources into returns. At -15852.13%, 4591.T may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -163513.51% in the prior-year period — up 90.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 4591.T's profit margin (-15852.13%), review year-over-year change from -163513.51%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.